{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:35:45Z","timestamp":1761989745816,"version":"build-2065373602"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed the therapeutic approach to diverse malignancies, leading to substantial enhancements in patient prognosis. However, along with their benefits, ICIs also increase the incidence of immune-related adverse events (irAEs). In the present paper, we highlight four cases of carpal tunnel syndrome (CTS) as an uncommon manifestation of toxicity induced by ICIs. Although diagnosed with different malignancies, the patients were undergoing ICI therapy when they developed CTS-consistent side effects accompanied by severe neuropathy. Prompt treatment with corticosteroids, intravenous immunoglobulins, or methotrexate resulted in complete symptomatic relief for all patients. This article therefore emphasizes the importance of recognizing and managing rare adverse events associated with ICI use to ensure optimal patient care.<\/jats:p>","DOI":"10.3390\/jpm13091340","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T09:44:46Z","timestamp":1693388686000},"page":"1340","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexander","family":"Yakobson","sequence":"first","affiliation":[{"name":"The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Rouvinov","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aharon Y.","family":"Cohen","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Neurology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University, Beer Sheva 84105, Israel"},{"name":"Department of Dermatology and Venereology, The Emek Medical Centre, Afula 18341, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University, Beer Sheva 84105, Israel"},{"name":"Department of Dermatology and Venereology, The Emek Medical Centre, Afula 18341, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Solomon","sequence":"additional","affiliation":[{"name":"Medical School for International Health and Sciences, Ben-Gurion University, Beer-Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Dudnik","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-4550","authenticated-orcid":false,"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[{"name":"The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Shalata, W., Zolnoorian, J., Migliozzi, G., Jama, A.A., Dudnik, Y., Cohen, A.Y., Meirovitz, A., and Yakobson, A. (2023). Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065938"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Szeto, C.H., Shalata, W., Yakobson, A., and Agbarya, A. (2021). Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235614"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Shalata, W., Massalha, I., Ishay, S.Y., Chernomordikova, E., Jama, A.A., Rouvinov, K., Dudnik, Y., and Yakobson, A. (2023). Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review. Life, 13.","DOI":"10.3390\/life13071585"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a036863","DOI":"10.1101\/cshperspect.a036863","article-title":"New Approaches on Cancer Immunotherapy","volume":"10","author":"Cha","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1161048","DOI":"10.3389\/fonc.2023.1161048","article-title":"The role of immunotherapy in microsatellites stable metastatic colorectal cancer: State of the art and future perspectives","volume":"13","author":"Gandini","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ijgc-2022-003758","article-title":"Advances in immunotherapy in cervical cancer","volume":"33","author":"Grau","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102545","DOI":"10.1016\/j.ctrv.2023.102545","article-title":"Immunotherapy-based combinations in metastatic NSCLC","volume":"116","author":"Desai","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shalata, W., Abu-Salman, A., Steckbeck, R., Mathew Jacob, B., Massalha, I., and Yakobson, A. (2021). Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13205218"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Shalata, W., Weissmann, S., Itzhaki Gabay, S., Sheva, K., Abu Saleh, O., Jama, A.A., Yakobson, A., and Rouvinov, K. (2022). A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14215451"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune Checkpoint Inhibitors-Induced Autoimmunity: The Impact of Gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_18","first-page":"1","article-title":"A Retrospective Analysis of Cardiovascular Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"7","author":"Lal","year":"2021","journal-title":"Cardiooncology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and Interleukin-6 Are Prognostic Factors for Autoimmune Toxicity Following Treatment With Anti-CTLA4 Blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J. Trans. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-Checkpoint Inhibitors Associated With Interstitial Lung Disease in Cancer Patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clml.2021.01.010","article-title":"Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies","volume":"21","author":"Gesiotto","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/07357907.2020.1721521","article-title":"Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis","volume":"38","author":"Sher","year":"2020","journal-title":"Cancer Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001935","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of Severe Immune-Related Adverse Events Requiring Hospital Admission in Patients on Immune Checkpoint Inhibitors: Study of a Population Level Insurance Claims Database From the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e002890","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5603\/FM.a2021.0121","article-title":"Carpal tunnel syndrome: State-of-the-art review","volume":"81","author":"Osiak","year":"2022","journal-title":"Folia Morphol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: A pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1242\/jcs.042762","article-title":"The T-cell-receptor signaling network","volume":"122","author":"Huse","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1074-7613(01)00097-8","article-title":"CTLA-4 regulates induction of anergy in vivo","volume":"14","author":"Greenwald","year":"2001","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yakobson, A., Abu Jama, A., Abu Saleh, O., Michlin, R., and Shalata, W. (2023). PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15164041"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_38","unstructured":"FDA (2023, June 06). Highlights of Prescribing Information: Atezolizumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s033s034s035s036s037s038lbl.pdf."},{"key":"ref_39","unstructured":"FDA (2023, June 06). Highlights of Prescribing Information: Durvalumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761069s002lbl.pdf."},{"key":"ref_40","unstructured":"(2012). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases. Avelumab: 23 June 2022."},{"key":"ref_41","unstructured":"FDA (2023, June 03). Highlights of Prescribing Information: Avelumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s096lbl.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CJI.0000000000000344","article-title":"Carpal Tunnel Syndrome: A New Adverse Effect of Immune Checkpoint Inhibitors, 11 Cases","volume":"44","author":"Lechevalier","year":"2021","journal-title":"J. Immunother."},{"key":"ref_43","unstructured":"FDA (2023, June 03). Highlights of Prescribing Information: Pembrolizumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"ref_44","unstructured":"FDA (2023, June 03). Highlights of Prescribing Information: Nivolumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125554s090lbl.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000507278","article-title":"Associated Myocarditis: A Predictive Factor for Response?","volume":"13","author":"Shalata","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_46","unstructured":"FDA (2023, March 16). Highlights of Prescribing Information: Cemiplimab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761097s007lbl.pdf."},{"key":"ref_47","unstructured":"FDA (2023, June 03). Highlights of Prescribing Information: Ipilimumab, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125377s110lbl.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/os.13705","article-title":"Bilateral Idiopathic Carpal Tunnel Syndrome: Clinical-Functional Characterization and Efficacy of Two Combined Postoperative Physiotherapeutic Treatments","volume":"15","author":"Georgeto","year":"2023","journal-title":"Orthop. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e020166","DOI":"10.1136\/bmjopen-2017-020166","article-title":"Trends in the prevalence, incidence and surgical management of carpal tunnel syndrome between 1993 and 2013: An observational analysis of UK primary care records","volume":"8","author":"Burton","year":"2018","journal-title":"BMJ Open"},{"key":"ref_50","first-page":"e7333","article-title":"Carpal Tunnel Syndrome: A Review of Literature","volume":"12","author":"Genova","year":"2020","journal-title":"Cureus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical Challenges of Immune Checkpoint Inhibitors","volume":"38","author":"Calvo","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Shalata, W., Yakobson, A., Cohen, A.Y., Goldstein, I., Saleh, O.A., Dudnik, Y., and Rouvinov, K. (2023). Unexpected Adverse Events of Immune Checkpoint Inhibitors. Life, 13.","DOI":"10.3390\/life13081657"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Electronic address: Clinicalguidelines@esmo.org. Management of toxici-ties from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Falvo, E., Diviccaro, S., Melcangi, R.C., and Giatti, S. (2020). Physiopathological Role of Neuroactive Steroids in the Peripheral Nervous System. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239000"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1007105121765","article-title":"The action of steroid hormones on peripheral myelin proteins: A possible new tool for the rebuilding of myelin?","volume":"29","author":"Melcangi","year":"2000","journal-title":"J. Neurocytol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neuroscience.2013.10.043","article-title":"Effects of progesterone on neuropathic pain responses in an experimental animal model for peripheral neuropathy in the rat: A behavioral and electrophysiological study","volume":"256","author":"Jarahi","year":"2014","journal-title":"Neuroscience"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","article-title":"Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms","volume":"13","author":"Jensen","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pneurobio.2013.09.004","article-title":"Revisiting the roles of progesterone and allopregnanolone in the nervous system: Resurgence of the progesterone receptors","volume":"113","author":"Schumacher","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsbmb.2015.03.002","article-title":"New steps forward in the neuroactive steroid field","volume":"153","author":"Giatti","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neuroscience.2008.06.034","article-title":"Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury","volume":"155","author":"Roglio","year":"2008","journal-title":"Neuroscience"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/j.1532-2149.2013.00376.x","article-title":"Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain","volume":"18","author":"Coronel","year":"2014","journal-title":"Eur. J. Pain"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/9\/1340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:43:04Z","timestamp":1760128984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/9\/1340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jpm13091340"],"URL":"https:\/\/doi.org\/10.3390\/jpm13091340","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}